Antibody-drug Conjugate Information

General Information of This Antibody-drug Conjugate (ADC)

ADC ID	DRG0ARHOG
ADC Name	BIIB-015
Synonyms	BIIB 015; BIIB015; Anti-CRIPTO; Anti-Cripto mAB; Anti-Cripto-DM4 Click to Show/Hide
Organization	Biogen, Inc.
Drug Status	Phase 1
Indication	In total 1 Indication(s) Solid tumors [ICD11:2A00-2A0Z\|2B50-2F9Z] Phase 1
Drug-to-Antibody Ratio	3-4
Structure
	3D MOL	2D MOL
Antibody Name	Anti-TDGF1 mAb huB3F6		Antibody Info
Antigen Name	Teratocarcinoma-derived growth factor 1 (TDGF1)		Antigen Info
Payload Name	Mertansine DM4		Payload Info
Therapeutic Target	Microtubule (MT)		Target Info
Linker Name	N-succinimidyl 4-(2-pyridyldithio) butanoate (SPDB)		Linker Info
Conjugate Type	Random conjugation through nucleophilic lysines.
Combination Type	Ravtansine
Puchem SID	160703950
Drugbank ID	DB06304
ChEBI ID	CHEMBL2109575

General Information of The Activity Data Related to This ADC

Identified from the Human Clinical Data

Click To Hide/Show 1 Activity Data Related to This Level

Standard Type	NCT Number	Clinical Status	Clinical Trial Description
Undisclosed	NCT00674947	Phase 1	A phase 1 study of B2B015, a humanized, IgG1, DM4-conjugated, anti-cripto, monoclonal antibody, for the treatment of subjects with relapsed or refractory solid tumors.

Discovered Using Cell Line-derived Xenograft Model

Click To Hide/Show 1 Activity Data Related to This Level

Standard Type	Value	Units	Cell Line	Disease Model
Tumor Growth Inhibition value (TGI)	≈ 53.4	%	MDA-MB-231 cells	Breast adenocarcinoma

Full List of Activity Data of This Antibody-drug Conjugate

Identified from the Human Clinical Data

Click To Hide/Show 1 Activity Data Related to This Level

Experiment 1 Reporting the Activity Date of This ADC				[1]
*Related Clinical Trial*
NCT Number	NCT00674947	Clinical Status	Phase 1
Clinical Description	A phase 1 study of B2B015, a humanized, IgG1, DM4-conjugated, anti-cripto, monoclonal antibody, for the treatment of subjects with relapsed or refractory solid tumors.

Discovered Using Cell Line-derived Xenograft Model

Click To Hide/Show 1 Activity Data Related to This Level

Experiment 1 Reporting the Activity Date of This ADC					[2]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 53.40% (Day 33)	High TDGF1 expression (TDGF1+++)
Method Description	NCCIT cells were inoculated into 8-week old male athymic nude mice. MDA-MB-231 cells were inoculated into 7-week old female CB17 SCID mice. Calu-6,human non-small cell lung cancer cells (ATCC) were maintained in MEM Earless BSS/NEAA/10%FBS media without antibiotics and inoculated subcutaneously (SC) into the right flank of 9-week old female athymic nude mice. For the CT-3 tumour model,primary human colon tumour tissue was serially transplanted in vivo to establish a SC xenograft model. Cryopreserved tumour fragments were thawed and serially passaged SC in female SCID beige mice at 810 weeks old for two to five generations prior to implantation for studies. Click to Show/Hide
In Vivo Model	MDA-MB-231 xenograft model
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062

References

Ref 1	A Phase I Study of BIIB015, a Humanized, IgG1, DM4-Conjugated, Anti-Cripto, Monoclonal Antibody, for the Treatment of Subjects With Relapsed or Refractory Solid Tumors, NCT00674947
Ref 2	An antibody-cytotoxic conjugate, BIIB015, is a new targeted therapy for Cripto positive tumours. Eur J Cancer. 2011 Jul;47(11):1736-46.